Breaking News
Revolut secures US trading license and takes on Robinhood
Revolut has secured itself a US broker-dealer license and is now about to compete in the trading app market, according to CNBC.
This way the company will directly challenge US trading juggernauts Robinhood and eToro.
Read also: Exclusive: Interview with Katral-Nada Hassan, YAP
“Launching commission-free stock trading is the next logical step in our plans for the U.S. market. We are building a single app where people can manage all aspects of their finances, from banking and foreign exchange to cryptocurrency and stock trading,” Nik Storonsky, CEO and founder of Revolut, said.
Revolut is about to use DriveWealth to help bring its trading and investment platform to US customers.
“As a licensed broker-dealer in the U.S., we’re eager to break down common barriers to entry around stock trading such as account minimums and complex interfaces by enabling customers to invest commission-free through a user-friendly interface,” Storonsky added.
US CEO Ronald Oliveira told CNBC that prior to awarding the fintech its new licence, the Financial Industry Regulatory Authority (FINRA) “took a deep dive—they asked lots of questions because they wanted to see exactly what the consumer experience was. It took them a period of time to get comfortable, but we’re very happy they got there.”
[mc4wp_form id=”2736″]
Revolut is also working with regulators on its U.S. bank charter application in California, first reported by CNBC last year, said Oliveira. That process isn’t likely to be completed this year, he said.
- The European Central Bank Selects Almaviva and Fabrick for Digital Euro Project Read more
- EXCLUSIVE: “The Advantage of Ancient Errors” – Tony Fish in ‘Discover Sibos 2025’ Read more
- EXCLUSIVE: “Game Changer” – Andy Lyons, Freemarket in ‘The Fintech Magazine’ Read more
- Binance Launches The Blockchain 100 Award to Honor Top Creators Driving Blockchain Innovation Read more
- MAPFRE AM Appoints Ismael García Puente as the New Deputy Director of Investment Strategy Read more